The top 10 things nephrologists wish every primary care physician knew

Mayo Clinic Proceedings

Volumn 84, Issue 2, 2009, Pages 180-186

  Paige, Neil M ^a,b   Nagami, Glenn T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALUMINUM HYDROXIDE; ALUMINUM MAGNESIUM HYDROXIDE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CARBAMAZEPINE; CEFOXITIN; CIMETIDINE; CITRIC ACID; COTRIMOXAZOLE; CREATININE; CYCLOSPORIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROMYCIN; FAMOTIDINE; FUROSEMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPERICUM PERFORATUM EXTRACT; MAGNESIUM CITRATE; METOLAZONE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYTOIN; PHOSPHATE BINDING AGENT; RANITIDINE; RECOMBINANT ERYTHROPOIETIN; RIFAMPICIN; SIMVASTATIN; TACROLIMUS; UNINDEXED DRUG; VERAPAMIL; ALUMINUM; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTACID AGENT; DRUG; IMMUNOSUPPRESSIVE AGENT; LAXATIVE; MAGNESIUM; PHOSPHATE; SODIUM DIHYDROGEN PHOSPHATE;

ANEMIA; BRAIN DISEASE; CHRONIC KIDNEY DISEASE; COMA; CONFUSION; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG BLOOD LEVEL; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY ALLOGRAFT; KIDNEY DISEASE; KIDNEY FAILURE; MEDICAL DECISION MAKING; MEDICAL SPECIALIST; MUSCLE MASS; MYOCLONUS; NEPHROLITHIASIS; NEPHROLOGIST; PATIENT REFERRAL; PRIMARY MEDICAL CARE; PROTEIN URINE LEVEL; PROTEINURIA; RECURRENT DISEASE; SEIZURE; SHORT SURVEY; SIDE EFFECT; ARTICLE; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CHEMISTRY; CHRONIC DISEASE; DRUG CONTRAINDICATION; DRUG INTERACTION; EVIDENCE BASED MEDICINE; NEPHROLOGY; PRIMARY HEALTH CARE; UREA NITROGEN BLOOD LEVEL; URINALYSIS; URINE;

ALUMINUM; ANEMIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTACIDS; BLOOD PRESSURE; BLOOD UREA NITROGEN; CARDIOVASCULAR DISEASES; CATHARTICS; CHRONIC DISEASE; CREATININE; CYCLOSPORINE; DISEASE PROGRESSION; DRUG INTERACTIONS; ERYTHROPOIETIN, RECOMBINANT; EVIDENCE-BASED MEDICINE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; MAGNESIUM; NEPHROLITHIASIS; NEPHROLOGY; PHARMACEUTICAL PREPARATIONS; PHOSPHATES; PRIMARY HEALTH CARE; PROTEINURIA; REFERRAL AND CONSULTATION; TACROLIMUS; URINALYSIS;

EID: 61449203840     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/84.2.180     Document Type: Review

References (43)

1. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67(6):2089-2100.
2. Fadem SZ. MDRD GFR Calculator (With SI Units): Web site. 4 variable MDRD study equation using serum creatinine, age, race, gender. http://www.mdrd.com/. Accessed December 17, 2008.
3. Stevens L, Perrone RD. Drugs that elevate the serum creatinine concentration UpToDate Online. http://uptodateonline.com/online/content/topic. do?topicKey=fldlytes/32725&selectedTitle=2~150&source=search-result. Accessed December 17, 2008.
4. Kannel WB, Stampfer MJ, Castelli WP, Verter J. The prognostic significance of proteinuria: the Framingham study. Am Heart J. 1984;108(5):1347-1352.
5. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification, Part 5: evaluation of laboratory measurements for clinical assessment of kidney disease guideline 5. assessment of proteinuria. NKF K/ DOQI Web site. http://www.kidney.org/Professionals/Kdoqi/ guidelines-ckd/p5-lab-g5.htm. Accessed December 17, 2008.
6. Ginsberg JM, Chang BS, Matarese RA, Garella S. Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med. 1983;309(25):1543-1546.
7. Schwab SJ, Christensen RL, Dougherty K, Klahr S. Quantitation of proteinuria by the use of protein-to-creatinine ratios in single urine samples. Arch Intern Med. 1987;147(5):943-944.
8. Warren GV, Korbet SM, Schwartz MM, Lewis EJ. Minimal change glomerulopathy associated with nonsteroidal antiinflammatory drugs. Am J Kidney Dis. 1989 Feb;13(2):127-130.
9. Burstein DM, Korbet SM, Schwartz MM. Membranous glomerulonephritis and malignancy. Am J Kidney Dis. 1993;22(1):5-10.
10. Brueggemeyer CD, Ramirez G. Membranous nephropathy: a concern for malignancy. Am J Kidney Dis. 1987;9(1):23-26.
11. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification, part 4: definition and classification of stages of chronic kidney disease guideline 2. evaluation and treatment. NKF K/DOQI Web Site. http://www.kidney.org/Professionals/Kdoqi/ guidelines-ckd/p4-class-g2.htm. Accessed December 17, 2008.
12. Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int. 2005;67(3):799-812.
13. Douglas K, O'Malley PG, Jackson JL. Meta-analysis: the effect of statins on albuminuria. Ann Intern Med. 2006;145(2):117-124.
14. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification, part 7: stratification of risk for progression of kidney disease and development of cardiovascular disease guideline 13. Factors associated with loss of kidney function in chronic kidney disease. NKF K/DOQI Web Site. http://www.kidney.org/Professionals/Kdoqi/ guidelines-ckd/p7-risk-g13.htm. Accessed December 17, 2008.
15. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008 Jan 1;148(1):30-48. Epub 2007 Nov 5.
16. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med. 2000;160(5):685-693.
17. Levin A, Thompson CR, Ethier J, et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis. 1999;34(1):125-134.
18. K/DOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis. 2007;50(3):471-530.
19. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet. 2007;369(9559):381-388.
20. Drüeke TB, Locatelli F, Clyne N, et al; CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355(20):2071-2084.
21. Singh AK, Szczech L, Tang KL, et al; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085-2098.
22. Fine A, Patterson J. Severe hyperphosphatemia following phosphate administration for bowel preparation in patients with renal failure: two cases and a review of the literature. Am J Kidney Dis. 1997;29(1):103-105.
23. Vukasin P, Weston LA, Beart RW. Oral Fleet Phospho-Soda laxative-induced hyperphosphatemia and hypocalcemic tetany in an adult: report of a case. Dis Colon Rectum. 1997;40(4):497-499.
24. Ullah N, Yeh R, Ehrinpreis M. Fatal hyperphosphatemia from a phosphosoda bowel preparation. J Clin Gastroenterol. 2002;34(4):457-458.
25. Markowitz GS, Stokes MB, Radhakrishnan J, D'Agati VD. Acute phosphate nephropathy following oral sodium phosphate bowel purgative: an underrecognized cause of chronic renal failure. J Am Soc Nephrol. 2005 Nov;16(11):3389-3396. Epub 2005 Sep 28.
26. Makkar R, Shen B. What are the caveats to using sodium phosphate agents for bowel preparation? Cleve Clin J Med. 2008;75(3):173-176.
27. Wexner SD, Beck DE, Baron TH, et al; American Society of Colon and Rectal Surgeons; American Society for Gastrointestinal Endoscopy; Society of American Gastrointestinal and Endoscopic Surgeons. A consensus document on bowel preparation before colonoscopy: prepared by a task force from the American Society of Colon and Rectal Surgeons (ASCRS), the American Society for Gastrointestinal Endoscopy (ASGE), and the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) [published correction appears in Gastrointest Endosc. 2006;64(1):154]. Gastrointest Endosc. 2006;63(7):894-909.
28. Alfrey AC. Aluminum toxicity in patients with chronic renal failure. Ther Drug Monit. 1993;15(6):593-597.
29. Drüeke TB. Intestinal absorption of aluminium in renal failure. Nephrol Dial Transplant. 2002;17(suppl 2):13-16.
30. Yokel RA. The toxicology of aluminum in the brain: a review. Neurotoxicology. 2000;21(5):813-828.
31. Coburn JW, Mischel MG, Goodman WG, Salusky IB. Calcium citrate markedly enhances aluminum absorption from aluminum hydroxide. Am J Kidney Dis. 1991;17(6):708-711.
32. Walker JA, Sherman RA, Cody RP. The effect of oral bases on enteral aluminum absorption. Arch Intern Med. 1990;150(10):2037-2039.
33. Bakir AA, Hryhorczuk DO, Ahmed S, et al. Hyperaluminemia in renal failure: the influence of age and citrate intake. Clin Nephrol. 1989;31(1):40-44.
34. Kirschbaum BB, Schoolwerth AC. Acute aluminum toxicity associated with oral citrate and aluminum-containing antacids. Am J Med Sci. 1989;297(1):9-11.
35. Danielson M, Dammström B. The prevalence of secondary and curable hypertension. Acta Med Scand. 1981;209(6):451-455.
36. Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res. 2004;27(3):193-202.
37. Trewet CL, Ernst ME. Resistant hypertension: identifying causes and optimizing treatment regimens. South Med J. 2008;101(2):166-173.
38. Calhoun DA. Resistant or difficult-to-treat hypertension. J Clin Hypertens (Greenwich). 2006;8(3):181-186.
39. Fang LS-T. Approach to the patient with nephrolithiasis. In: Goroll AH, May LA, Mulley AG, eds. Primary Care Medicine: Office Evaluation and Management of the Adult Patient. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2000:782-787.
40. Preminger GM. The metabolic evaluation of patients with recurrent nephrolithiasis: a review of comprehensive and simplified approaches. J Urol 1989;141(3, pt 2):760-763.
41. Kourambas J, Aslan P, Teh CL, Mathias BJ, Preminger GM. Role of stone analysis in metabolic evaluation and medical treatment of nephrolithiasis. J Endourol. 2001;15(2):181-186.
42. Pak CYC, Griggith DP, Menin M, Preminger GM, Resnick, MI. ABCs of Medical Management of Stones. 2003 revised ed. http://www.abcsofstonedisease.com/. Accessed December 22, 2008.
43. Magee CC. Pharmacology and side effects of cyclosporine and tacrolimus UpToDate Online 16.3. http://uptodateonline.com/online/content/topic.do? topicKey=tx-rheum/8690&selectedTitle=4~150&source=search-results. Accessed December 22, 2008.